Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target
Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $12 price target.
Read original at benzingaStocks · News reference
Coya Therapeutics Q2 EPS $(0.28) Beats $(0.34) Estimate, Sales $243.745K Beat $100.000K Estimate
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.34) by 17.65 percent. This is a 22.22 percent increase over losses of $(0.36) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 12:11 PM
- Checked
- Aug 11, 2026, 12:11 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Coya Therapeutics, Inc. (COYA)
Filed: 2026-08-11 AccNo: 0001193125-26-343473 Size: 452 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar8-K/A filing — Coya Therapeutics, Inc. (COYA)
Filed: 2026-08-07 AccNo: 0001193125-26-340449 Size: 146 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgar